28 results on '"Eric Bergoend"'
Search Results
2. Heart Transplantation, Either Alone or Combined With Liver and Kidney, a Viable Treatment Option for Selected Patients With Severe Cardiac Amyloidosis
- Author
-
Soulef Guendouz, MD, Philippe Grimbert, MD, PhD, Costin Radu, MD, PhD, Daniel Cherqui, MD, PhD, Chady Salloum, MD, Nicolas Mongardon, MD, PhD, Sami Maghrebi, MD, Karim Belhadj, MD, Fabien Le Bras, MD, Emmanuel Teiger, MD, PhD, Jean-Paul Couetil, MD, PhD, Adriana Balan, MD, Mounira Kharoubi, MSc, Mélanie Bézard, MSc, Silvia Oghina, MD, Diane Bodez, MD, PhD, Luc Hittinger, MD, PhD, Vincent Audard, MD, PhD, Violaine Planté-Bordeneuve, MD, PhD, Alexandre De la Taille, MD, PhD, Eric Bergoend, MD, Valerie Frenkel, MD, PhD, Pascale Fanen, MD, PhD, Vincent Leroy, MD, PhD, Christophe Duvoux, MD, PhD, Maryvonnick Carmagnat, PharmD, Thierry Folliguet, MD, PhD, and Thibaud Damy, MD, PhD
- Subjects
Surgery ,RD1-811 - Abstract
Background. Heart transplantation in cardiac amyloidosis (CA) patients is possible and generally considered for transplantation if other organs are not affected. In this study, we aimed to describe and assess outcome in patients following heart transplantations at our CA referral center. Methods. We assessed all CA patients that had heart transplantations at our center between 2005 and 2018. Patients with New York Heart Association status 3 out of 4, with poor short-term prognosis due to heart failure, despite treatment, and without multiple myeloma, systemic disease, severe neuropathic/digestive comorbidities, cancer, or worsening infections were eligible for transplantation. Hearts were transplanted by bicaval technique. Standard induction and immunosuppressive therapies were used. Survival outcome of CA patients after transplantation was compared with recipients with nonamyloid pathologies in France. Results. Between 2005 and 2018, 23 CA patients had heart transplants: 17 (74%) had light chain (light chain amyloidosis [AL]) and 6 (26%) had hereditary transthyretin (hereditary transthyretin amyloidosis [ATTRv]) CA. Also, 13 (57%) were male, and the mean age at diagnosis was 56.5 y (range, 47.7–62.8). Among AL patients, 13 had heart-only and 5 had heart-kidney transplantations. Among ATTRv patients, 1 had heart-only and 5 had heart-liver transplantations. The 1-y survival rate after transplantation was 78%, 70% with AL, and 100% with ATTRv. At 2 y, 74% were alive: 65% with AL and 100% with ATTRv. Conclusion. After heart transplantation, French CA and nonamyloid patients have similar survival outcomes. Among CA patients, ATTRv patients have better prognosis than those with AL, possibly due to the combined heart-liver transplantation. Selected CA patients should be considered for heart transplantations.
- Published
- 2022
- Full Text
- View/download PDF
3. Causes and consequences of cardiac fibrosis in patients referred for surgical aortic valve replacement
- Author
-
Arnault Galat, Aziz Guellich, Diane Bodez, Larissa Lipskaia, Stéphane Moutereau, Eric Bergoend, Sophie Hüe, Julien Ternacle, Dania Mohty, Jean‐Luc Monin, Geneviève Derumeaux, Costin Radu, and Thibaud Damy
- Subjects
Aortic stenosis ,Cardiac fibrosis ,Inflammation ,IL‐6 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Aims Cardiac fibrosis is associated with left ventricular (LV) remodelling and contractile dysfunction in aortic stenosis (AS). The fibrotic process in this condition is still unclear. The aim of this study was to determine the role of both local and systemic inflammation as underlying mechanisms of LV fibrosis and contractile dysfunction. The diagnostic values of 2D‐strain echocardiography and serum biomarkers in the evaluation of cardiac fibrosis in this condition were assessed through correlation analyses. Methods and results Patients with AS referred for surgical valve replacement were prospectively and consecutively included. They all had a comprehensive echocardiography including 2D strain. Blood samples were collected to measure cytokines and inflammatory biomarkers using Luminex bead‐based assays. A per‐surgical myocardial biopsy of the basal antero‐septal segment (S1) was performed. Serial sections of each biopsy were stained with Sirius red. Digital image analysis was used to quantify fibrosis. Immunostainings using specific antibodies against macrophage, glycoprotein (gp) 130, and interleukin 6 (IL‐6) were also performed. Patients were divided into tertiles reflecting the severity of fibrosis: mild, moderate, and severe load (TF1 to TF3). The mean age of the 58 included patients was 73 ± 11 years. Twenty‐four (43%) were in New York Heart Association III–IV. Mean aortic valve area was 0.8 ± 0.2 cm2. Mean aortic stenosis peak velocity and mean gradient were respectively 4.5 ± 0.8 m/s and 54 ± 15 mmHg. The mean LV ejection fraction was 54 ± 12%, and the global LV longitudinal strain was −15 ± 4%. The mean S1 strain, corresponding to the biopsied region, was −10 ± 6% and was strongly correlated to fibrosis load (R = 0.83, P
- Published
- 2019
- Full Text
- View/download PDF
4. Postinflammatory rupture of right coronary artery ostium complicating Behçet disease
- Author
-
Antonio Fiore, Mariantonietta Piscitelli, Amel Rabia, Haytham Derbel, Eric Bergoend, Sanjeet S. Avtaar Singh, and Francesco Nappi
- Subjects
Pulmonary and Respiratory Medicine ,Surgery ,Cardiology and Cardiovascular Medicine - Published
- 2022
5. Timing of aortic valve replacement in high-gradient severe aortic stenosis: impact of left ventricular ejection fraction
- Author
-
Camille Deguillard, Thierry Folliguet, Damien Fard, Pascal Lim, Flavien Vincent, Geneviève Derumeaux, Annabelle Nguyen, Antonio Fiore, William Juguet, Gauthier Mouillet, Julien Ternacle, Eric Bergoend, Emmanuel Teiger, Louis Nahory, Athanasios Koutsoukis, and Romain Gallet
- Subjects
medicine.medical_specialty ,aortic valve replacement ,left ventricular dysfunction ,mortality ,Severe aortic stenosis ,TAVR ,Aortic Valve ,Humans ,Retrospective Studies ,Severity of Illness Index ,Stroke Volume ,Treatment Outcome ,Ventricular Function, Left ,Aortic Valve Stenosis ,Heart Valve Prosthesis Implantation ,Ventricular Dysfunction, Left ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Aortic valve replacement ,Internal medicine ,medicine ,030212 general & internal medicine ,Ejection fraction ,business.industry ,General Medicine ,medicine.disease ,Stenosis ,cardiovascular system ,Cardiology ,Risk of death ,Cardiology and Cardiovascular Medicine ,business - Abstract
Patients with high-gradient (HG) severe aortic stenosis (AS) and left ventricular (LV) dysfunction are at high risk of death. The optimal timing for aortic valve replacement (AVR) is not defined by guidelines. The objective was to define the optimal timing to perform isolated AVR in patients with HG-AS and severe LV dysfunction.We retrospectively included 233 consecutive patients admitted for severe HG-AS (aortic valve area1cmPatients with HG-AS and severe LV dysfunction had a higher risk profile than those with LVEF35%. AVR was performed in 93% (218/233) of patients, 41% by surgery (SAVR) and 53% by transcatheter (TAVR). TAVR was the preferred method to treat HG-AS patients with LVEF ≤35%. All-cause mortality while waiting for AVR was higher in patients with severe LV dysfunction (22% vs. 2.0%,AVR should be performed promptly after Heart Team decision in patients with HG severe AS and LVEF ≤35% because of a very high and premature risk of death while waiting for intervention.
- Published
- 2020
6. Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival
- Author
-
Mounira Kharoubi, Diane Bodez, Mélanie Bézard, Amira Zaroui, Arnault Galat, Soulef Guendouz, Thierry Gendre, Luc Hittinger, David Attias, Dania Mohty, Eric Bergoend, Emmanuel Itti, Fabien Lebras, David Hamon, Elsa Poullot, Valérie Molinier-Frenkel, Nicolas Lellouche, Jean-François Deux, Benoit Funalot, Pascale Fannen, Silvia Oghina, Raphael Arrouasse, Philippe Lecorvoisier, Sarah Souvannanorath, Aurelien Amiot, Emmanuel Teiger, Wulfran Bougouin, and Thibaud Damy
- Subjects
Heart Failure ,Amyloid Neuropathies, Familial ,Death, Sudden ,Internal Medicine ,Humans ,Amyloidosis ,Cardiomyopathies ,Retrospective Studies - Abstract
The three main cardiac amyloidosis (CA) types have different progression and prognosis. Little is known about the mode of death (MOD) which is commonly attributed to cardiovascular causes in CA. Improving MOD’s knowledge could allow to adapt patient care. This retrospective study describes the MOD that occurred during long-term follow-up in CA patients in light-chain (AL), transthyretin hereditary (ATTRv) or wild-type (ATTRwt). Patients referred to and cared for, at the French referral centre for CA, Henri Mondor Hospital, Créteil between 2010 and 2016 were included. Clinical information surrounding patient deaths were investigated and centrally evaluated by two blinded clinical committees which classified MOD as cardiovascular, non-cardiovascular or unknown and sub-classified it depending on its subtype. From the 566 patients included, 187 had AL, 206 ATTRv and 173 ATTRwt. During the 864 patient-year follow-up, 160 (28%) deaths occurred, with median survival time of 17.3 months (interquartile range 5.1–35.4). The most frequent MOD was cardiovascular (64%) of which worsening heart failure occurred most frequently and for which, 69% were of AL subtype, 79% ATTRv and 76% ATTRwt. Sudden death also occurred more frequently in AL subtype accounting for 29% of AL deaths. Non-cardiovascular MOD occurred in 26% of patients overall. Among these, infection was the most common non-cardiovascular MOD in any type of CA (80%). Mortality is high during natural course of CA and differs between subtypes. The main MOD were worsening heart failure, sudden death and infection, opening room to optimise management.
- Published
- 2022
- Full Text
- View/download PDF
7. Aortic valve repair versus mechanical valve replacement for root aneurysm: the CAVIAAR multicentric study
- Author
-
Emmanuel Lansac, Isabelle Di Centa, Pichoy Danial, Olivier Bouchot, Eric Arnaud-Crozat, Rachid Hacini, Fabien Doguet, Roland Demaria, Jean Philippe Verhoye, Jerome Jouan, Didier Chatel, Stephane Lopez, Thierry Folliguet, Pascal Leprince, Thierry Langanay, Christian Latremouille, Georges Fayad, Jean Philippe Fleury, Jean Luc Monin, Leila Mankoubi, Milena Noghin, Alain Berrebi, Sarah Pousset, Aline Laubriet-Jazayeri, Alexandre Lafourcade, Estelle Marcault, Michel Kindo, Laurent Payot, Eric Bergoend, Cecile Jourdain Hoffart, Mathieu Debauchez, and Florence Tubach
- Subjects
Pulmonary and Respiratory Medicine ,Reoperation ,Heart Valve Prosthesis Implantation ,Aortic Valve Insufficiency ,General Medicine ,Middle Aged ,Cardiac Valve Annuloplasty ,Aortic Aneurysm ,Treatment Outcome ,Aortic Valve ,Quality of Life ,Humans ,Surgery ,Prospective Studies ,Cardiology and Cardiovascular Medicine ,Retrospective Studies - Abstract
OBJECTIVES Despite growing evidence that aortic valve repair improves long-term patient outcomes and quality of life, aortic valves are mostly replaced. We evaluate the effect of aortic valve repair versus replacement in patients with dystrophic aortic root aneurysm up to 4 years. METHODS The multicentric CAVIAAR (Conservation Aortique Valvulaire dans les Insuffisances Aortiques et les Anévrismes de la Racine aortique) prospective cohort study enrolled 261 patients: 130 underwent standardized aortic valve repair (REPAIR) consisting of remodelling root repair with expansible aortic ring annuloplasty, and 131 received mechanical composite valve and graft replacement (REPLACE). Primary outcome was a composite criterion of mortality, reoperation, thromboembolic or major bleeding events, endocarditis or operating site infections, pacemaker implantation and heart failure, analysed with propensity score-weighted Cox model analysis. Secondary outcomes included major adverse valve-related events and components of primary outcome. RESULTS The mean age was 56.1 years, and valve was bicuspid in 115 patients (44.7%). Up to 4 years, REPAIR did not significantly differ from REPLACE in terms of primary outcome [Hazard Ratio (HR) 0.66 (0.39; 1.12)] but showed significantly less valve-related deaths (HR 0.09 [0.02; 0.34]) and major bleeding events (HR 0.37 [0.16; 0.85]) without an increased risk of valve-related reoperation (HR 2.10 [0.64; 6.96]). When accounting for the occurrence of multiple events in a single patient, the REPAIR group had half the occurrence of major adverse valve-related events (HR 0.51 [0.31; 0.86]). CONCLUSIONS Although the primary outcome did not significantly differ between the REPAIR and REPLACE groups, the trend is in favour of REPAIR by a significant reduction of valve-related deaths and major bleeding events. Long-term follow-up beyond 4 years is needed to confirm these findings.
- Published
- 2021
8. Should We Quantify Valvular Calcifications on Cardiac CT in Patients with Infective Endocarditis?
- Author
-
Pascal Lim, Raphaelle Huguet, Vania Tacher, Remi Valter, Amina Moussafeur, Thierry Folliguet, Virgile Chevance, Islem Sifaoui, Mohamed Refaat Nouri, Sebastien Mule, Florence Canoui-Poitrine, Eric Bergoend, Raphael Lepeule, and Jean-François Deux
- Subjects
medicine.medical_specialty ,Atypical bacteria ,Cardiac computed tomography ,business.industry ,cardiac imaging techniques ,Mortality rate ,endocarditis bacterial ,valve calcium scoring ,General Medicine ,medicine.disease ,Article ,Embolism ,Infective endocarditis ,Internal medicine ,Cardiology ,cardiovascular system ,Medicine ,In patient ,Aortic calcifications ,cardiovascular diseases ,business ,cardiac computed tomography ,Calcium score - Abstract
Background: Evaluate the impact of valvular calcifications measured on cardiac computed tomography (CCT) in patients with infective endocarditis (IE). Methods: Seventy patients with native IE (36 aortic IE, 31 mitral IE, 3 bivalvular IE) were included and explored with CCT between January 2016 and April 2018. Mitral and aortic valvular calcium score (VCS) were measured on unenhanced calcium scoring images, and correlated with clinical, surgical data, and 1-year death rate. Results: VCS of patients with mitral IE and no peripheral embolism was higher than those with peripheral embolism (868 (25–1725) vs. 6 (0–95), p <, 0.05). Patients with high calcified mitral IE (mitral VCS >, 100, n = 15) had a lower rate of surgery (40.0% vs.78.9%, p = 0.03) and a higher 1-year-death risk (53.3% vs. 10.5%, p = 0.04, OR = 8.5 (2.75–16.40) than patients with low mitral VCS (n = 19). Patients with aortic IE and high aortic calcifications (aortic VCS >, n = 18) present more frequently atypical bacteria on blood cultures (33.3% vs. 4.8%, p = 0.03) than patients with low aortic VCS (n = 21). Conclusion: The amount of valvular calcifications on CT was associated with embolism risk, rate of surgery and 1-year risk of death in patients with mitral IE, and germ’s type in aortic IE raising the question of their systematic quantification in native IE.
- Published
- 2021
9. Floating thrombus in the ascending aorta revealed by peripheral arterial embolism
- Author
-
Khaoula Boughanmi, Mariantonietta Piscitelli, Nora Chanai, Eric Bergoend, Majdi Gueldich, Thierry Folliguet, Antonio Fiore, and Haytham Derbel
- Subjects
Adult ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Embolism ,Aortic Diseases ,law.invention ,Lesion ,law ,medicine.artery ,Internal medicine ,Ascending aorta ,medicine ,Cardiopulmonary bypass ,Humans ,Thrombus ,Stroke ,Thrombectomy ,Aorta ,business.industry ,Arterial Embolization ,Thrombosis ,Middle Aged ,medicine.disease ,cardiovascular system ,Cardiology ,Female ,Surgery ,medicine.symptom ,Tomography, X-Ray Computed ,Cardiology and Cardiovascular Medicine ,business - Abstract
A floating thrombus in the ascending aorta is rarely found in clinical practice and is an uncommon cause of peripheral arterial embolization. When there is minimal atherosclerosis or a normal aorta, the management of such a lesion is poorly defined. Currently, there is no clear consensus concerning optimal treatment. Herein, we report 2 cases of ascending aortic thrombus that are complicated by a peripheral embolic event. Due to the risk of recurrent systemic embolism, particularly with strokes, surgical thrombectomy with ascending aortic wall replacements was performed. We believe that floating ascending aorta thrombus represents a serious source of systemic embolism and stroke. Surgical removal is easy to perform with good clinical outcomes. Conservative treatments such as anticoagulation or thromboaspiration may be considered in high-risk or inoperable patients.
- Published
- 2020
10. Causes and consequences of cardiac fibrosis in patients referred for surgical aortic valve replacement
- Author
-
Aziz Guellich, Julien Ternacle, Eric Bergoend, Larissa Lipskaia, Diane Bodez, Arnault Galat, Costin Radu, Geneviève Derumeaux, Thibaud Damy, Jean-Luc Monin, Sophie Hüe, Stéphane Moutereau, and Dania Mohty
- Subjects
Male ,lcsh:Diseases of the circulatory (Cardiovascular) system ,medicine.medical_specialty ,Cardiac fibrosis ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Aortic valve replacement ,Valve replacement ,Fibrosis ,Original Research Articles ,Internal medicine ,Biopsy ,medicine ,Humans ,Prospective Studies ,Original Research Article ,030212 general & internal medicine ,Aged ,Aged, 80 and over ,Heart Valve Prosthesis Implantation ,Inflammation ,Ejection fraction ,medicine.diagnostic_test ,business.industry ,Myocardium ,Aortic stenosis ,Aortic Valve Stenosis ,IL‐6 ,Middle Aged ,medicine.disease ,Stenosis ,lcsh:RC666-701 ,Heart failure ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Aims Cardiac fibrosis is associated with left ventricular (LV) remodelling and contractile dysfunction in aortic stenosis (AS). The fibrotic process in this condition is still unclear. The aim of this study was to determine the role of both local and systemic inflammation as underlying mechanisms of LV fibrosis and contractile dysfunction. The diagnostic values of 2D‐strain echocardiography and serum biomarkers in the evaluation of cardiac fibrosis in this condition were assessed through correlation analyses. Methods and results Patients with AS referred for surgical valve replacement were prospectively and consecutively included. They all had a comprehensive echocardiography including 2D strain. Blood samples were collected to measure cytokines and inflammatory biomarkers using Luminex bead‐based assays. A per‐surgical myocardial biopsy of the basal antero‐septal segment (S1) was performed. Serial sections of each biopsy were stained with Sirius red. Digital image analysis was used to quantify fibrosis. Immunostainings using specific antibodies against macrophage, glycoprotein (gp) 130, and interleukin 6 (IL‐6) were also performed. Patients were divided into tertiles reflecting the severity of fibrosis: mild, moderate, and severe load (TF1 to TF3). The mean age of the 58 included patients was 73 ± 11 years. Twenty‐four (43%) were in New York Heart Association III–IV. Mean aortic valve area was 0.8 ± 0.2 cm2. Mean aortic stenosis peak velocity and mean gradient were respectively 4.5 ± 0.8 m/s and 54 ± 15 mmHg. The mean LV ejection fraction was 54 ± 12%, and the global LV longitudinal strain was −15 ± 4%. The mean S1 strain, corresponding to the biopsied region, was −10 ± 6% and was strongly correlated to fibrosis load (R = 0.83, P
- Published
- 2019
11. Aortic Valve Surgery in Nonelderly Patients: Insights Gained From AVIATOR
- Author
-
Jean-François Fuzellier, Christophe de Meester, Rémi Houel, Florence Tubach, Georges Fayad, Maciej Matuszewski, Eric Arnaud-Crozat, Svenja Rauch, Jean-François Obadia, Adrian Kolesar, Matteo Pettinari, Bardia Arabkhani, Jos A. Bekkers, Fabrizio Ceresa, Andrea Mangini, Dave R. Koolbergen, Daniel Czytrom, František Sabol, Thomas J van Brakel, Ignacio Bibiloni, Pallav Shah, Rosina Ziller, Alain Leguerrier, Marek Jasiński, Gianclaudio Mecozzi, Mihail Svetkin, Taoufik Benkacem, Jaroslav Hlubocky, Hans-Joachim Schäfers, Vincent Doisy, Jean-Luc Monin, Christine Leon, Carlo Antona, Jan Vojacek, Munir Boodhwani, Francesco Patane, Andrey Slautin, Gebrine Elkhoury, Rubina Rosa, Yutaka Okita, Ismail El-Hamamsy, Wenke Goossens, Alain Berrebi, Paolo Ferrero, Jan Nijs, Fabien Doguet, Mauro Masat, Monica Contino, Edward P. Chen, Gregorio Rábago, Stéphane Lopez, Duke E. Cameron, Johannes Steindl, José Aramendi, Eric Bergoend, Maurice Enriquez-Sarano, Jean-Louis Vanoverschelde, Bart Meuris, Virginia Alvarez-Asiain, Robert Novotny, Davor Barić, Michael A. Borger, Tomas Toporcer, Ruggero De Paulis, Leila Mankoubi, J. M. Marnette, Christelle Diakov, Amaia Melero, Said Soliman, Michael Tousch, Ryan E. Accord, Philippe Pibarot, Mikita Karalko, Vladislav Aminov, Agnes Pasquet, Serban Stoica, David Messika Zeitoun, Olivier Bouchot, Bernard Albat, Jérôme Jouan, Savica Gjorgijevska, Klaartje Van den Bossche, Igor Rudez, J. Kluin, Laurent de Guillaume Jondeau, Didier Chatel, Pascal Leprince, Sarah Pousset, Rafael Sadaba, Veerle Van Mossevelde, Evi Schepmans, Johanna J.M. Takkenberg, Carlos Porras, Herbert Gutermann, Isabelle Di Centa, Aude Boignard, Joseph E. Bavaria, Pierre-Emmanuel Noly, Yves Glock, Corinne Coulon, Bart Loeys, Rita K. Milewski, Christian Dinges, Marien Lenoir, Francesco Grigioni, Alejandro Crespo, Patrick Moeller, Frederiek de Heer, Mohamad Bashir, Milean Noghin, Fadoua Kaddouri, Takashi Kunihara, Isaac Wenger, Ilaria Chirichilli, Claudia Romagnoni, Diana Aicher, Arturo Evangelista Masip, Daniel Unić, Emmanuel Lansac, Fabrice Wautot, Peter Verbrugghe, Laurent de Kerchove, Pouya Youssefi, Josip Varvodić, Robert J.M. Klautz, Patrick Yiu, Frank Theisohn, Pavel Zacek, Guy Fernandez, Takeshi Miyairi, Thierry Bourguignon, Cardiothoracic Surgery, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, and UCL - (SLuc) Service de chirurgie cardiovasculaire et thoracique
- Subjects
Aortic valve ,Time Factors ,Nonelderly patients ,medicine.medical_treatment ,Heart Valve Diseases ,AVIATOR ,Aortic valve surgery ,Adult ,Age Factors ,Aortic Valve ,Bioprosthesis ,Evidence-Based Medicine ,Heart Valve Prosthesis ,Life Expectancy ,Middle Aged ,Prosthesis Failure ,Recovery of Function ,Registries ,Risk Factors ,Treatment Outcome ,Heart Valve Prosthesis Implantation ,Transcatheter Aortic Valve Replacement ,030204 cardiovascular system & hematology ,0302 clinical medicine ,Aortic valve repair ,Quality of life ,Expectancy theory ,education.field_of_study ,Ross procedure ,General Medicine ,medicine.anatomical_structure ,Cardiology and Cardiovascular Medicine ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Population ,03 medical and health sciences ,medicine ,Humans ,education ,business.industry ,Mechanical Aortic Valve ,Surgery ,Settore MED/23 ,030228 respiratory system ,Life expectancy ,business - Abstract
Aortic valve surgery in non-elderly patients represents a very challenging patient population. The younger the patient is at the point of aortic valve intervention, the longer their anticipated life expectancy will be, with longer exposure to valve-related complications and risk for re-operation. Although the latest international guidelines recommend aortic valve repair in patients with aortic valve insufficiency, what we see in the real world is that the vast majority of these aortic valves are replaced. However, current prosthetic valves has now been shown to lead to significant loss of life expectancy for non-elderly patients up to 50% for patients in their 40s undergoing mechanical aortic valve replacement. Bioprostheses carry an even worse long-term survival, with higher rates of re-intervention. The promise of trans-catheter valve-in-valve technology is accentuating the trend of bioprosthetic implantation in younger patients, without yet the appropriate evidence. In contrast, aortic valve repair has shown excellent outcomes in terms of quality of life, freedom from re-operation and freedom from major adverse valve-related events with similar life expectancy to general population as it is also found for the Ross procedure, the only available living valve substitute. We are at a time when the paradigm of aortic valve surgery needs to change for the better. To better serve our patients, we must acquire high quality real-world evidence from multiple centers globally - this is the vision of the AVIATOR registry and our common responsibility.
- Published
- 2019
12. Valvular surgery in donor hearts before orthotopic heart transplantation
- Author
-
Amir Youssari, Julien Ternacle, Eric Bergoend, Jean Paul Couetil, Antonio Fiore, Mariantonietta Piscitelli, Giuseppe Gatti, Nicolas Mongardon, Antonino M. Grande, CHU Henri Mondor, Fondazione Ospedale San Camillo [Venezia] (IRCCS), University hospital of Trieste, Institut Mondor de Recherche Biomédicale (IMRB), and Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
- Subjects
Male ,Aortic valve ,Mitral Valve Annuloplasty ,Time Factors ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,030204 cardiovascular system & hematology ,Heart transplantation ,Transplantation cardiaque ,0302 clinical medicine ,Aortic valve replacement ,Risk Factors ,Medicine ,030212 general & internal medicine ,Heart Valve Prosthesis Implantation ,Donneurs marginaux ,Graft Survival ,Calcinosis ,Mitral Valve Insufficiency ,General Medicine ,Middle Aged ,Remplacement de la valve aortique ,Tissue Donors ,3. Good health ,Treatment Outcome ,medicine.anatomical_structure ,Aortic Valve ,Aortic valve stenosis ,cardiovascular system ,Mitral Valve ,Female ,Cardiology and Cardiovascular Medicine ,medicine.medical_specialty ,Heart valve surgery ,Donor Selection ,03 medical and health sciences ,Humans ,Organ donation ,Heart Failure ,Mitral valve repair ,Mitral regurgitation ,business.industry ,Donor selection ,Marginal donors ,Réparation de la valve mitrale ,Aortic Valve Stenosis ,Feasibility Studies ,Recovery of Function ,Heart Transplantation ,medicine.disease ,Surgery ,business - Abstract
Summary Background Donor heart shortage has extended the waiting time and increased the mortality of patients on the transplant waiting list. Widening old standard donor criteria has successfully increased the number of heart transplantations, but for many years, a valve disease in a donor heart has been considered a primary contraindication for organ donation. Aims To analyse the results of aortic and mitral valvular surgery in marginal donor hearts with valvulopathy before orthotopic heart transplantation. Methods Between January 2012 and November 2015, we performed 53 heart transplantations in our department. In four donors, echocardiography performed at the time of organ procurement showed a valvular disease: three had moderate-to-severe mitral regurgitation; and one had moderately severe aortic valve stenosis. Results The mean bench mitral repair and aortic replacement time, aortic cross-clamp time and total ischaemic time were: 18 (range 7–25) minutes, 78.7 (range 57–98) minutes and 184 (range 89–255) minutes, respectively. Intraoperative transoesophageal echocardiography showed good mitral repair or aortic prosthetic valve function, and good right and left ventricular function. One patient died of infectious pneumonia after 1 month. The mean duration of follow-up for the patients discharged home was 75 ± 13 months, and all have returned to an active unrestricted lifestyle. Conclusions Our limited series demonstrates that conventional valvular procedures performed on otherwise healthy donor hearts with mitral and aortic valve pathology can efficaciously expand the donor pool for orthotopic cardiac transplantation and decrease the mortality rate on the waiting list.
- Published
- 2020
13. A New Three-Dimensional Echocardiography Method to Quantify Aortic Valve Calcification
- Author
-
Laureline Faivre, Antonio Fiore, Thomas d’Humières, Jean-Paul Couetil, Geneviève Derumeaux, Damien Fard, Nicole Benhaiem, Pascal Lim, Elie Chammous, Jean-Luc Dubois-Randé, Jean-François Deux, Costin Radu, Julien Ternacle, and Eric Bergoend
- Subjects
Male ,Aortic valve ,3D echocardiography ,Aortic valve stenosis ,Calcium scoring ,Echocardiography, Three-Dimensional ,Regurgitation (circulation) ,030204 cardiovascular system & hematology ,Severity of Illness Index ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,030212 general & internal medicine ,Aged ,business.industry ,Ultrasound ,Calcinosis ,Reproducibility of Results ,Three dimensional echocardiography ,Aortic Valve Stenosis ,medicine.disease ,Stenosis ,medicine.anatomical_structure ,Aortic Valve ,cardiovascular system ,Female ,Aortic valve calcification ,Cardiology and Cardiovascular Medicine ,Nuclear medicine ,business ,Echocardiography, Transesophageal ,Follow-Up Studies ,Calcification - Abstract
Background Aortic valve calcification (AVC) quantification is computed from multidetector computed tomography (MDCT). The aim of this study was to test the hypothesis that three-dimensional (3D) transthoracic echocardiography can be used to provide a bedside method to assess AVC. Methods The study included 94 patients (mean age, 78 ± 12 years; mean aortic valve [AV] area, 1.0 ± 0.6 cm2) referred for MDCT and echocardiography for AV assessment. Apical 3D full-volume data sets focused on the AV region were acquired during transthoracic echocardiography, and a region-growing algorithm was applied offline to compute 3D transthoracic echocardiographic AVC (AVC-3DEcho). AVC-3DEcho was compared with AVC by MDCT and with calcium weight in the subgroup of patients referred for surgery, with explanted AVs analyzed by a pathologist (n = 22). Results In the explanted valve group, AVC-3DEcho score exhibited fair correlations with MDCT score (r = 0.85, P 1,054 mm3 identified severe aortic stenosis with specificity of 100% and sensitivity of 76%. In addition, AVC-3DEcho was associated with the presence of significant paravalvular regurgitation after transcatheter aortic valve implantation. Finally, intraobserver and interobserver variability for AVC-3DEcho score was 4.2% and 8.9%, respectively. Conclusions AVC-3DEcho correlated with calcium weight obtained from pathologic analysis and MDCT. These data suggest that a bedside method for quantifying AV calcification with ultrasound is feasible.
- Published
- 2018
14. Successful percutaneous treatment of an anomalous left circumflex coronary artery occlusion after tricuspid valve repair
- Author
-
Julien Ternacle, Hélène Hergault, Gauthier Mouillet, and Eric Bergoend
- Subjects
Pulmonary and Respiratory Medicine ,Aorta ,medicine.medical_specialty ,Percutaneous ,Valve surgery ,business.industry ,medicine.medical_treatment ,Percutaneous coronary intervention ,Circumflex branch of left coronary artery ,Coronary occlusion ,medicine.artery ,Internal medicine ,Occlusion ,cardiovascular system ,medicine ,Cardiology ,Surgery ,cardiovascular diseases ,TRICUSPID VALVE REPAIR ,Cardiology and Cardiovascular Medicine ,business - Abstract
The risk of coronary artery injury during valve surgery is higher in case of anomalous coronary artery origin and trajectory. Unlike previous reports on coronary obstruction related to aortic or mitral surgery, we report the first case, to the best of our knowledge, of an anomalous left circumflex artery occlusion after tricuspid valve repair, and its successful percutaneous treatment.
- Published
- 2019
15. The convergent procedure: a hybrid approach for long lasting persistent atrial fibrillation ablation
- Author
-
Clément Bars, David Hamon, Wissam Alam, Frederic A. Sebag, Nicolas Lellouche, Julien Ternacle, Eric Bergoend, Miche Fahed, Thierry Folliguet, and Konstantinos Zannis
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Recurrence ,Risk Factors ,Internal medicine ,Atrial Fibrillation ,medicine ,Humans ,Diaphragmatic hernia ,Sinus rhythm ,Stroke ,Aged ,Retrospective Studies ,business.industry ,Thoracoscopy ,Atrial fibrillation ,General Medicine ,Middle Aged ,medicine.disease ,Ablation ,Progression-Free Survival ,030228 respiratory system ,Cardiothoracic surgery ,Heart failure ,Cardiology ,Catheter Ablation ,Surgery ,Female ,Tamponade ,France ,Cardiology and Cardiovascular Medicine ,business ,Anti-Arrhythmia Agents - Abstract
Background Atrial fibrillation (AF) is associated with increased risk of stroke, heart failure and all-cause mortality. The Cox-Maze procedure is the most effective approach to ablate persistent AF but presents a significant morbidity and mortality. Additionally, the classical endocardial ablation approach has limited efficacy to treat long lasting persistent AF. We described a new, minimally invasive hybrid approach, combining an endocardial and epicardial ablation named convergent procedure to treat long lasting persistent AF patients. Methods We studied 55 consecutive patients with long lasting persistent AF who underwent the convergent procedure in 2 French centers between 2010 and 2015. All patients had at least one previous failed endocardial ablation and were highly symptomatic. Patients with a history of thoracic surgery were excluded. A 24 hour-Holter ECG was performed systematically at 3, 6 and 12 months after the convergent procedure. All patients reached 1-year follow-up. Results No death, stroke, phrenic nerve palsy or tamponade occurred immediately after the procedure. Post-surgery average length of stay was 8±4 days. Later, 3 patients (5%) developed diaphragmatic hernia resulting in a modified surgery technique. At 12 months, 76% of patients were in sinus rhythm after an average of 1.43 ablation procedure. Finally, 91% of patients were maintained on antiarrhythmic drugs. Conclusions Thoracoscopic hybrid epicardial-endocardial ablation technique proved to be effective and safe to treat long lasting persistent AF patients with previous failed endocardial AF ablation.
- Published
- 2019
16. Temporal Trends in Transcatheter Aortic Valve Replacement in France
- Author
-
Vincent Auffret, Thierry Lefevre, Eric Van Belle, Hélène Eltchaninoff, Bernard Iung, René Koning, Pascal Motreff, Pascal Leprince, Jean Philippe Verhoye, Thibaut Manigold, Geraud Souteyrand, Dominique Boulmier, Patrick Joly, Frédéric Pinaud, Dominique Himbert, Jean Philippe Collet, Gilles Rioufol, Said Ghostine, Olivier Bar, Alain Dibie, Didier Champagnac, Lionel Leroux, Frédéric Collet, Emmanuel Teiger, Olivier Darremont, Thierry Folliguet, Florence Leclercq, Thibault Lhermusier, Patrick Olhmann, Bruno Huret, Luc Lorgis, Laurent Drogoul, Bernard Bertrand, Christian Spaulding, Laurent Quilliet, Thomas Cuisset, Maxence Delomez, Farzin Beygui, Jean-Philippe Claudel, Alain Hepp, Arnaud Jegou, Antoine Gommeaux, Anfani Mirode, Luc Christiaens, Charles Christophe, Claude Cassat, Damien Metz, Lionel Mangin, Karl Isaaz, Laurent Jacquemin, Philippe Guyon, Christophe Pouillot, Serge Makowski, Vincent Bataille, Josep Rodés-Cabau, Martine Gilard, Hervé Le Breton, Herve Le Breton, Marc Laskar, Bernard Chevalier, Philippe Garot, Thomas Hovasse, Patrick Donzeau Gouge, Arnaud Farge, Mauro Romano, Bertrand Cormier, Erik Bouvier, Jean-Jacques Bauchart, Jean-Christophe Bodart, Cédric Delhaye, David Houpe, Robert Lallemant, Fabrice Leroy, Arnaud Sudre, Francis Juthier, Mohamed Koussa, Thomas Modine, Natacha Rousse, Jean-Luc Auffray, Marjorie Richardson, Jacques Berland, Mathieu Godin, Jean-Paul Bessou, Vincent Letocart, Jean-Christian Roussel, Philippe Jaafar, Nicolas Combaret, Nicolas D’Ostrevy, Andréa Innorta, Guillaume Clerfond, Charles Vorilhon, Marc Bedossa, Guillaume Leurent, Amedeo Anselmi, Majid Harmouche, Jean-Philippe Verhoye, Erwan Donal, Jacques Bille, Rémi Houel, Bertrand Vilette, Wissam Abi Khalil, Stéphane Delepine, Olivier Fouquet, Frédéric Rouleau, Jérémie Abtan, Marina Urena, Soleiman Alkhoder, Walid Ghodbane, Dimitri Arangalage, Eric Brochet, Coppelia Goublaire, Olivier Barthelemy, Rémi Choussat, Jean-Philippe Collet, Guillaume Lebreton, Chiro Mastrioanni, Richard Isnard, Raphael Dauphin, Olivier Dubreuil, Guy Durand De Gevigney, Gérard Finet, Brahim Harbaoui, Sylvain Ranc, Fadi Farhat, Olivier Jegaden, Jean-François Obadia, Matteo Pozzi, Saïd Ghostine, Philippe Brenot, Sahbi Fradi, Alexandre Azmoun, Philippe Deleuze, Martin Kloeckner, Didier Blanchard, Christophe Barbey, Stephan Chassaing, Didier Chatel, Olivier Le Page, Arnaud Tauran, Didier Bruere, Laurent Bodson, Yvon Meurisse, Aurélien Seemann, Nicolas Amabile, Christophe Caussin, Simon Elhaddad, Luc Drieu, Alice Ohanessian, François Philippe, Aurélie Veugeois, Matthieu Debauchez, Konstantinos Zannis, Daniel Czitrom, Chrystelle Diakov, François Raoux, Yves Lienhart, Patrick Staat, Oualid Zouaghi, Vincent Doisy, Jean Philippe Frieh, Fabrice Wautot, Julie Dementhon, Olivier Garrier, Fadi Jamal, Pierre Yves Leroux, Frédéric Casassus, Benjamin Seguy, Laurent Barandon, Louis Labrousse, Julien Peltan, Claire Cornolle, Marina Dijos, Stéphane Lafitte, Gilles Bayet, Claude Charmasson, Alain Vaillant, Jacques Vicat, Marie Paule Giacomoni, Eric Bergoend, Céline Zerbib, Jean Louis Leymarie, Philippe Clerc, Emmanuel Choukroun, Nicolas Elia, Jean-Philippe Grimaud, Jean-Philippe Guibaud, Stéphane Wroblewski, Eric Abergel, Emmanuel Bogino, Christophe Chauvel, Patrick Dehant, Marc Simon, Michel Angioi, Julien Lemoine, Simon Lemoine, Batric Popovic, Pablo Maureira, Olivier Huttin, Christine Selton Suty, Guillaume Cayla, Delphine Delseny, Gilles Levy, Jean Christophe Macia, Eric Maupas, Christophe Piot, François Rivalland, Gabriel Robert, Laurent Schmutz, Frédéric Targosz, Bernard Albat, Arnaud Dubar, Nicolas Durrleman, Thomas Gandet, Emmanuel Munos, Stéphane Cade, Frédéric Cransac, Frédéric Bouisset, Etienne Grunenwald, Bertrand Marcheix, Pauline Fournier, Olivier Morel, Patrick Ohlmann, Michel Kindo, Minh Tam Hoang, Hélène Petit, Hafida Samet, Anne Trinh, Guillaume Lecoq, Jean François Morelle, Pascal Richard, Thierry Derieux, Emmanuel Monier, Cédric Joret, Olivier Bouchot, Jean Christophe Eicher, Pierre Meyer, Stéphane Lopez, Michel Tapia, Jacques Teboul, Jean-Pierre Elbeze, Alain Mihoubi, Gérald Vanzetto, Olivier Wittenberg, Vincent Bach, Cécile Martin, Carole Sauier, Charlotte Casset, Philippe Castellant, Eric Bezon, Jean-Noel Choplain, Ahmed Kallifa, Bahaa Nasr, Yannick Jobic, Antoine Lafont, Jean-Yves Pagny, Ramzi Abi Akar, Jean-Noël Fabiani, Rachid Zegdi, Alain Berrebi, Tania Puscas, Bernard Desveaux, Fabrice Ivanes, Christophe Saint Etienne, Thierry Bourguignon, Blandine Aupy, Romain Perault, Jean-Louis Bonnet, Marc Lambert, Dominique Grisoli, Nicolas Jaussaud, Erwan Salaun, Amine Laghzaoui, Christine Savoye, Mathieu Bignon, Vincent Roule, Rémy Sabatier, Calin Ivascau, Vladimir Saplacan, Eric Saloux, Damien Bouchayer, Guillaume Tremeau, Camille Diab, Joel Lapeze, Franck Pelissier, Thomas Sassard, Catherine Matz, Nicolas Monsarrat, Ivan Carel, Franck Sibellas, Alain Curtil, Grégoire Dambrin, Xavier Favereau, Gabriel Ghorayeb, Laurent Guesnier, Wassim Khoury, Christophe Kucharski, Bruno Pouzet, Claude Vaislic, Riadh Cheikh-Khelifa, Loïc Hilpert, Philippe Maribas, Gery Hannebicque, Philippe Hochart, Marc Paris, Max Pecheux, Olivier Fabre, Laurent Leborgne, Marcel Peltier, Faouzi Trojette, Doron Carmi, Christophe Tribouilloy, Jean Mergy, Pierre Corbi, Pascale Raud Raynier, Sylvain Carillo, Arnaud Hueber, Fédéric Moulin, Georges Pinelli, Nicole Darodes, Francis Pesteil, Chadi Aludaat, Frédéric Torossian, Loïc Belle, Nicolas Chavanis, Chrystelle Akret, Alexis Cerisier, Jean Pierre Favre, Jean François Fuzellier, Romain Pierrard, Olivier Roth, Jean Yves Wiedemann, Nicolas Bischoff, Georghe Gavra, Nicolas Bourrely, Franck Digne, Mohammed Najjari, Victor Stratiev, Nicolas Bonnet, Patrick Mesnildrey, David Attias, Julien Dreyfus, Daniel Karila Cohen, Thierry Laperche, Julien Nahum, Aliocha Scheuble, Geoffrey Rambaud, Eric Brauberger, Michel Ah Hot, Philippe Allouch, Fabrice Beverelli, Julien Rosencher, Stéphane Aubert, Jean Michel Grinda, Thierry Waldman, Service de cardiologie et maladies vasculaires, Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle ( MIVEGEC ), Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche pour le Développement ( IRD [France-Sud] ), Service de cardiologie [Rouen], CHU Rouen-Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Service de cardiologie, Assistance publique - Hôpitaux de Paris (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ), CHU Gabriel Montpied ( CHU ), CHU Clermont-Ferrand, Institut Pascal - Clermont Auvergne ( IP ), Sigma CLERMONT ( Sigma CLERMONT ) -Université Clermont Auvergne ( UCA ) -Centre National de la Recherche Scientifique ( CNRS ), Service de chirurgie cardiaque et thoracique [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Laboratoire Traitement du Signal et de l'Image ( LTSI ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de chirurgie cardio-vasculaire et thoracique, CHU Angers, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition ( ICAN ), CHU Pitié-Salpêtrière [APHP]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Université Pierre et Marie Curie - Paris 6 ( UPMC ), Adaptation cardiovasculaire à l'ischemie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut Mondor de recherche biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Service de cardiologie [Toulouse], Université Paul Sabatier - Toulouse 3 ( UPS ) -CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Cochin [AP-HP], Nutrition, obésité et risque thrombotique ( NORT ), Institut National de la Recherche Agronomique ( INRA ) -Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), CHU de Poitiers, Epidémiologie et Biostatistique, Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps [Toulouse], Université Paul Sabatier - Toulouse 3 ( UPS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Optimisation des régulations physiologiques ( ORPHY (EA 4324) ), Université de Brest ( UBO ) -Institut Brestois du Numérique et des Mathématiques ( IBNM ), Université de Brest ( UBO ) -Université de Brest ( UBO ), Institut de Chimie de la Matière Condensée de Bordeaux ( ICMCB ), Université de Bordeaux ( UB ) -Centre National de la Recherche Scientifique ( CNRS ), Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Institut national de recherches archéologiques préventives ( Inrap ), Hémostase et pathologie cardiovasculaire, EA2693-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Lille, Droit et Santé, Belgian Institute for Space Aeronomy / Institut d'Aéronomie Spatiale de Belgique ( BIRA-IASB ), ONERA - The French Aerospace Lab ( Toulouse ), ONERA, Service de chirurgie thoracique cardiaque et vasculaire [Rennes], Institut de cardiologie [CHU Pitié-Salpêtrière], Service de Chirurgie Thoracique et Cardiovasculaire [CHU Pitié-Salpêtrière], Cardioprotection, Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Cardiovasculaire, métabolisme, diabétologie et nutrition ( CarMeN ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hospices Civils de Lyon ( HCL ) -Institut National des Sciences Appliquées de Lyon ( INSA Lyon ), Université de Lyon-Institut National des Sciences Appliquées ( INSA ) -Université de Lyon-Institut National des Sciences Appliquées ( INSA ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Institut National de la Recherche Agronomique ( INRA ), Carnegie Mellon University [Pittsburgh] ( CMU ), Hôpital nord, St Etienne, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Clinique du Tonkin, Unité de recherche Phytopharmacie et Médiateurs Chimiques ( UPMC ), Institut National de la Recherche Agronomique ( INRA ), Département de cardiologie, CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Centre des Sciences des Littératures en Langue Française ( CSLF ), Université Paris Nanterre ( UPN ), Service de Cardiologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Saint-Antoine [APHP], Laboratoire de Chimie Physique - Matière et Rayonnement ( LCPMR ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire d'Informatique Fondamentale de Lille ( LIFL ), Université de Lille, Sciences et Technologies-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Université de Lille, Sciences Humaines et Sociales-Centre National de la Recherche Scientifique ( CNRS ), Défaillance Cardiovasculaire Aiguë et Chronique ( DCAC ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Lorraine ( UL ), Centre Hospitalier Régional Universitaire de Nîmes ( CHRU Nîmes ), Service de chirurgie thoracique et cardio-vasculaire, Université Montpellier 1 ( UM1 ) -Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Hôpital Arnaud de Villeneuve, Institut des Maladies Métaboliques et Cardiovasculaires ( I2MC ), Université Paul Sabatier - Toulouse 3 ( UPS ) -Hôpital de Rangueil-Institut National de la Santé et de la Recherche Médicale ( INSERM ), École de sages-femmes René Rouchy ( ESF Angers ), Université d'Angers ( UA ) -CHU Angers, Laboratoire de Génie Civil et d'Ingénierie Environnementale ( LGCIE ), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon ( INSA Lyon ), Université de Lyon-Institut National des Sciences Appliquées ( INSA ) -Institut National des Sciences Appliquées ( INSA ), Agriculture and Agri-Food [Ottawa] ( AAFC ), Centre d'études et de recherche sur les contentieux - EA 3164 ( CERC ), Université de Toulon ( UTLN ), Radiopharmaceutiques biocliniques, Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Clinique de chirurgie cardiaque, Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble, Unité Mixte de Recherches sur les Herbivores ( UMR 1213 Herbivores ), VetAgro Sup ( VAS ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Recherche Agronomique ( INRA ), Université Grenoble Alpes - UFR Médecine ( UGA UFRM ), Université Grenoble Alpes ( UGA ), Développement artériel, Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre de recherche en économie et management ( CREM ), Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Centre National de la Recherche Scientifique ( CNRS ), Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie ( UPMC ), Université Pierre et Marie Curie - Paris 6 ( UPMC ), Récepteurs nucléaires, maladies cardiovasculaires et diabète ( EGID ), Université de Lille, Droit et Santé-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut Pasteur de Lille, Réseau International des Instituts Pasteur ( RIIP ) -Réseau International des Instituts Pasteur ( RIIP ) -Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Edwards Lifesciences Medtronic Lead-Up Medicines Company French Cardiology Federation (Federation Francaise de Cardiologie) Eli Lilly WebMD Biosensor ACIST Abbott Biosensors Terumo Daichii-Sankyo Boston Scientific St. Jude Medical Bristol-Myers Squibb Bayer AstraZeneca French Ministry of Health Abiomed Zoll Medpass Cordis Servier, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Pitié-Salpêtrière [APHP], Centre hospitalier universitaire de Poitiers ( CHU Poitiers ), Institut Pasteur de Lille, and Réseau International des Instituts Pasteur ( RIIP ) -Réseau International des Instituts Pasteur ( RIIP ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille )
- Subjects
Aortic valve ,medicine.medical_specialty ,medicine.medical_treatment ,national registry ,030204 cardiovascular system & hematology ,outcomes ,03 medical and health sciences ,0302 clinical medicine ,Valve replacement ,Cardiac tamponade ,Medicine ,030212 general & internal medicine ,ComputingMilieux_MISCELLANEOUS ,Aortic dissection ,business.industry ,Mortality rate ,transfemoral ,EuroSCORE ,[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,medicine.disease ,pacemaker ,3. Good health ,Surgery ,Stenosis ,Catheter ,medicine.anatomical_structure ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background - Transcatheter aortic valve replacement (TAVR) is standard therapy for patients with severe aortic stenosis who are at high surgical risk. However, national data regarding procedural characteristics and clinical outcomes over time are limited. Objectives - The aim of this study was to assess nationwide performance trends and clinical outcomes of TAVR during a 6-year period. Methods - TAVRs performed in 48 centers across France between January 2013 and December 2015 were prospectively included in the FRANCE TAVI (French Transcatheter Aortic Valve Implantation) registry. Findings were further compared with those reported from the FRANCE 2 (French Aortic National CoreValve and Edwards 2) registry, which captured all TAVRs performed from January 2010 to January 2012 across 34 centers. Results - A total of 12,804 patients from FRANCE TAVI and 4,165 patients from FRANCE 2 were included in this analysis. The median age of patients was 84.6 years, and 49.7% were men. FRANCE TAVI participants were older but at lower surgical risk (median logistic European System for Cardiac Operative Risk Evaluation [EuroSCORE]: 15.0% vs. 18.4%; p < 0.001). More than 80% of patients in FRANCE TAVI underwent transfemoral TAVR. Transesophageal echocardiography guidance decreased from 60.7% to 32.3% of cases, whereas more recent procedures were increasingly performed in hybrid operating rooms (15.8% vs. 35.7%). Rates of Valve Academic Research Consortium-defined device success increased from 95.3% in FRANCE 2 to 96.8% in FRANCE TAVI (p < 0.001). In-hospital and 30-day mortality rates were 4.4% and 5.4%, respectively, in FRANCE TAVI compared with 8.2% and 10.1%, respectively, in FRANCE 2 (p
- Published
- 2017
17. Spontaneous mechanical rupture of a papillary muscle effectively resolved by mitral valve repair
- Author
-
Antonio Fiore, Mariantonietta Piscitelli, Jean Paul Couetil, and Eric Bergoend
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Mitral Valve Annuloplasty ,Heart Diseases ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Papillary muscle ,Medicine ,Humans ,Mitral valve repair ,Mitral valve regurgitation ,Rupture, Spontaneous ,business.industry ,Mitral Valve Insufficiency ,General Medicine ,Papillary muscle rupture ,Middle Aged ,Papillary Muscles ,medicine.anatomical_structure ,030228 respiratory system ,Cardiology ,Surgery ,Female ,Cardiology and Cardiovascular Medicine ,business ,Left ventricular wall - Abstract
We report a case of spontaneous mechanical papillary muscle rupture. In theory, the papillary muscle works as a shock absorber that compensates for geometric changes of left ventricular wall. We believe that the aetiology of papillary muscle rupture, in this case, is linked to the physical and mechanical strains exerted on the papillary. We performed a mitral valve repair with excellent short- and long-term results.
- Published
- 2017
18. Is bilateral internal thoracic artery grafting a safe option for chronic dialysis patients?
- Author
-
Eric Bergoend, Antonio Fiore, Giuseppe Gatti, Andrea Perrotti, Sidney Chocron, Gianfranco Sinagra, Jean-Paul Couetil, Aniello Pappalardo, Gatti, Giuseppe, Perrotti, Andrea, Fiore, Antonio, Bergoend, Eric, Chocron, Sidney, Couetil, Jean-Paul, Sinagra, Gianfranco, and Pappalardo, Aniello
- Subjects
Male ,Arterial graft ,Coronary artery bypass graft ,Dialysis ,Quality improvement ,Renal failure ,Survival ,medicine.medical_treatment ,Coronary Artery Disease ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,Coronary artery disease ,0302 clinical medicine ,Postoperative Complications ,Risk Factors ,Odds Ratio ,Hospital Mortality ,Aged, 80 and over ,Dialysi ,General Medicine ,Treatment Outcome ,Italy ,Cardiology ,Female ,France ,Patient Safety ,Cardiology and Cardiovascular Medicine ,medicine.medical_specialty ,Grafting (decision trees) ,Clinical Decision-Making ,Internal thoracic artery ,Disease-Free Survival ,03 medical and health sciences ,Renal Dialysis ,medicine.artery ,Internal medicine ,Ascending aorta ,medicine ,Humans ,Propensity Score ,Internal Mammary-Coronary Artery Anastomosis ,Aged ,Retrospective Studies ,Chi-Square Distribution ,business.industry ,Patient Selection ,Odds ratio ,medicine.disease ,Confidence interval ,Surgery ,Logistic Models ,030228 respiratory system ,Propensity score matching ,Multivariate Analysis ,Kidney Failure, Chronic ,business - Abstract
Summary Background The use of bilateral internal thoracic artery (BITA) grafting has been proposed for dialysis patients with multivessel coronary artery disease, primarily because of hypothetical long-term survival benefits. Aims To investigate the outcome of BITA grafting in dialysis patients. Methods This was a retrospective analysis of the use of BITA grafting in 105 consecutive patients with end-stage renal failure on chronic dialysis in three European centres with extensive experience in BITA. Baseline patient characteristics, operative data, early postoperative complications and late survival were reviewed. Outcomes of patients from one of the three centres who underwent either BITA (n = 40) or single internal thoracic artery (SITA) grafting (n = 19) were also analysed; a one-to-one propensity score (PS)-matched analysis was performed. Results There were 19 (18.1%) hospital deaths. Despite differences in preoperative patient characteristics and surgical features, in each centre, hospital mortality was greater than the 75th percentile of expected operative risk (EuroSCORE II). Diseased ascending aorta and extracardiac arteriopathy were found to be predictors of hospital death (odds ratio 9.7; P = 0.006) and complicated hospital course (odds ratio 2.54; P = 0.035), respectively. The 7-year non-parametric estimates of freedom from all-cause death and cardiac or cerebrovascular death were 59% (95% confidence interval: 52.3–65.7%) and 75.6% (95% confidence interval: 71.2–80%), respectively. There were no significant differences in early and late outcomes between BITA and SITA PS-matched groups. Conclusions BITA grafting remains a risky operation for chronic dialysis patients, even when performed routinely. No long-term survival benefits for the use of BITA versus SITA were proven.
- Published
- 2017
19. Mode of death in cardiac amyloidosis
- Author
-
F. Lebras, Dania Mohty, J.L. Dubois-Randé, David Attias, S. Guendouz, Wulfran Bougouin, Violaine Planté-Bordeneuve, Diane Bodez, Eric Bergoend, E. Itti, Luc Hittinger, Mounira Kharoubi, Arnault Galat, T. Damy, and Jean Francois Deux
- Subjects
medicine.medical_specialty ,biology ,business.industry ,Amyloidosis ,medicine.disease ,Sudden death ,Transthyretin ,Cardiac amyloidosis ,Heart failure ,Internal medicine ,medicine ,AL amyloidosis ,biology.protein ,Cardiology and Cardiovascular Medicine ,business ,Stroke ,Cause of death - Abstract
Introduction Cardiac amyloidosis (CA) is a severe disease, often lethal. Little is known about cause of death during the natural course of CA. Identification of cause of death during CA is of particular interest to design clinical trials and identify therapeutic targets in this pathology. We aimed to describe mode of death in CA patients during long-term follow-up, according to the type of amyloidosis. Material and methods All patients consecutively referred to the French referral center for light-chain (AL), transthyretin hereditary (hTTR) or wild-type (WT-TTR) CA were consecutively included between 2010 and 2016 were included. Mode of death was centrally adjudicated by two blinded clinical committees, using multiple sources, and classified as cardiovascular (including worsening heart failure, sudden death, stroke) or non-cardiovascular (1). Results From the 565 patients included, 187 patients had AL amyloidosis, 220 had hTTR and 158 had WT-TTR amyloidosis. One hundred thirty-nine patients (25%) died during a follow-up of 864 patients-years, with median follow-up in survivors 14.6 months (IQR 3.7–33.9). One-year survival was 67% in AL patients, 92% in hTTR patients and 89% in WT-TTR patients (logrank Discussion and Conclusions Mortality is high during natural course of cardiac amyloidosis, significantly different according to CA type. Main causes of death were cardiovascular (mostly worsening heart failure and sudden death), opening room for optimal prevention and management.
- Published
- 2019
20. Patients without prolonged QRS after TAVI with CoreValve device do not experience high-degree atrio-ventricular block
- Author
-
Kentaro Meguro, Pascal Lim, Jean-François Deux, Jean-Luc Dubois-Randé, Emmanuel Teiger, Nicolas Lellouche, Gauthier Mouillet, Jean-Luc Monin, Masanori Yamamoto, and Eric Bergoend
- Subjects
medicine.medical_specialty ,education.field_of_study ,medicine.diagnostic_test ,business.industry ,Population ,EuroSCORE ,General Medicine ,medicine.disease ,Surgery ,QRS complex ,Internal medicine ,Aortic valve stenosis ,Heart rate ,medicine ,Cardiology ,Radiology, Nuclear Medicine and imaging ,Cardiology and Cardiovascular Medicine ,Prospective cohort study ,business ,education ,Chi-squared distribution ,Electrocardiography - Abstract
Objective To identify clinical and electrical factors predicting delayed high-degree atrio-ventricular block (AVB) after transcatheter aortic valve implantation (TAVI). Background TAVI is a new technique for treating severe aortic valve stenosis in patients at high surgical risk but can be followed by high-grade AVB requiring permanent pacing (PP). Methods and Results The study included 79 patients (82 ± 17 years, Euroscore = 23% ± 10%) free of PP need before and immediately after TAVI procedure. Delayed high-degree AVB was defined by types 2 or 3 AVB diagnosed at least 24 hr after the index procedure. Permanent pacemaker implantation was performed for all these patients. We compared clinical and electrical variables before and after TAVI in patients with delayed AVB or not. TAVI was performed successfully in all patients. The 21 (26%) patients who exhibited delayed high-grade AVB had significantly deeper prosthesis implantation (12 ± 4 mm vs. 9 ± 5 mm, P = 0.03) and wider post-TAVI QRS duration (155 ± 17 msec vs. 131 ± 25 msec, P = 0.0004), with no difference in baseline QRS duration. Post-TAVI QRS duration was the only independent predictor of post-TAVI permanent for delayed high-degree AVB (P = 0.02). After a mean follow-up of 10 ± 8 months, all 21 patients with post-TAVI QRS ≤128 msec were free of high-grade AVB, whereas 21/55 (38%) patients with post-TAVI QRS >128 msec had PP (P = 0.0016). Conclusion Delayed (>24 hr after the procedure) high-grade AVB necessitating PP is common after TAVI. QRS duration measured immediately after TAVI was the best independent predictor of PP in this population. Patients with QRS ≤128 msec immediately after TAVI had no risk of requiring PP. © 2012 Wiley, Periodicals, Inc.
- Published
- 2012
21. Pulmonary Artery Dissection: A Case Treated by Homograft Replacement
- Author
-
Eric Bergoend, Didier K. Adodo, Jean-Paul Couetil, and Martin Kloeckner
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,Male ,medicine.medical_specialty ,030204 cardiovascular system & hematology ,Pulmonary Artery ,Chest pain ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,law ,medicine.artery ,Pulmonary arterial trunk ,medicine ,Cardiopulmonary bypass ,Humans ,Pulmonary artery dissection ,business.industry ,Emergency department ,medicine.disease ,Allografts ,Pulmonary hypertension ,Surgery ,Blood Vessel Prosthesis ,Stenosis ,Aortic Dissection ,030228 respiratory system ,Echocardiography ,Pulmonary artery ,Radiology ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Tomography, X-Ray Computed ,Vascular Surgical Procedures - Abstract
Pulmonary artery dissection was diagnosed in a 32-year-old man who was admitted to the emergency department with intense chest pain. He had a history of pulmonary balloon valvuloplasty for congenital pulmonary stenosis at the age of 7 and no pulmonary hypertension. The operation was performed with cardiopulmonary bypass. The dissected pulmonary arterial trunk was removed with the distorted valve, and replaced with a pulmonary artery homograft. The postoperative course was uneventful. Histologic examination revealed medionecrosis. Pulmonary artery dissection is a rare but highly lethal pathology. In the absence of pulmonary hypertension, surgical treatment with homograft replacement can lead to excellent results.
- Published
- 2016
22. Prognostic value of right ventricular systolic function in cardiac amyloidosis
- Author
-
Costin Radu, Luc Hittinger, Arnault Galat, Aziz Guellich, Dania Mohty, Jean-Paul Couetil, Soulef Guendouz, Pascal Lim, Diane Bodez, Jean-Luc Dubois-Randé, Jean-François Deux, Thibaud Damy, Violaine Planté-Bordeneuve, Julien Ternacle, and Eric Bergoend
- Subjects
Male ,medicine.medical_specialty ,Heart Ventricles ,Ventricular Dysfunction, Right ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,Doppler echocardiography ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Natriuretic Peptide, Brain ,Internal Medicine ,medicine ,Humans ,Prealbumin ,Prospective Studies ,Interventricular septum ,cardiovascular diseases ,Prospective cohort study ,Aged ,Aged, 80 and over ,Heart Failure ,Heart transplantation ,medicine.diagnostic_test ,business.industry ,Amyloidosis ,Stroke Volume ,Stroke volume ,Middle Aged ,Prognosis ,medicine.disease ,Magnetic Resonance Imaging ,Survival Analysis ,Echocardiography, Doppler ,Peptide Fragments ,medicine.anatomical_structure ,Cardiac amyloidosis ,Heart failure ,Cardiology ,cardiovascular system ,Heart Transplantation ,Female ,Immunoglobulin Light Chains ,Cardiomyopathies ,business ,030217 neurology & neurosurgery - Abstract
Right ventricular (RV) dysfunction is a strong predictor of poor outcomes in heart failure. Its prognostic meaning in cardiac amyloidosis (CA) is under-investigated.Hundred and twenty nine patients with suspected CA and an interventricular septum thickness (IVST) ≥ 12 mm underwent echocardiography with measurement of left ventricular (LV) and RV longitudinal strain (LS), late gadolinium-enhancement (LGE) cardiac MRI, and standard evaluation.Among 82 confirmed CA, types were immunoglobulin light chain (AL, n = 26), hereditary transthyretin (m-TTR, n = 37) and senile (WT-TTR, n = 19). Compared to those without, CA patients had significantly lower RV fractional shortening (RV-FS), tricuspid annular plane systolic excursion (TAPSE), tissue Doppler systolic velocity, and global RV-LS, without any difference among the CA types. RV-LGE, observed in 62% of CA patients, was associated with lower global and basal RV-FS. Median follow-up was 8(2; 16) months. Using multivariate analysis, NYHA-class and low TAPSE independently predicted major adverse cardiac event (MACE) defined as death, heart transplantation and acute heart failure. Independent determinants of TAPSE 14 mm, the best cut-off value, were LV ejection fraction (LVEF), estimated filling pressure (E/E'), NT-proBNP and pulmonary artery pressure, but not RV-LGE.RV dysfunction is common in CA. Its routine evaluation by a simple TAPSE may be an aid in assessing the prognosis of CA patients.
- Published
- 2016
- Full Text
- View/download PDF
23. Comparison of Effectiveness and Safety of Transcatheter Aortic Valve Implantation in Patients Aged ≥90 Years Versus <90 Years
- Author
-
Eric Bergoend, Pascal Lim, Jean-Luc Dubois-Randé, Emmanuel Teiger, Masanori Yamamoto, Kentaro Meguro, Gauthier Mouillet, and Jean-Luc Monin
- Subjects
Male ,medicine.medical_specialty ,Transcatheter aortic ,Population ,Risk Factors ,Internal medicine ,Prevalence ,Humans ,Medicine ,In patient ,Prospective Studies ,education ,Proportional Hazards Models ,Aged, 80 and over ,Heart Valve Prosthesis Implantation ,education.field_of_study ,Chi-Square Distribution ,Clinical screening ,business.industry ,Aortic Valve Stenosis ,medicine.disease ,Surgery ,Survival Rate ,Stenosis ,Treatment Outcome ,Aortic Valve ,Cardiology ,Female ,Patient Safety ,Radiology ,Cardiology and Cardiovascular Medicine ,business - Abstract
In a fraction of patients aged ≥90 years, less-invasive transcatheter aortic valve implantation (TAVI) has been considered a therapeutic option for aortic stenosis under careful clinical screening. However, the safety and effectiveness using TAVI in such a population has not been fully elucidated. The aim of the present study was to investigate the feasibility of TAVI in nonagenarians. We prospectively enrolled 136 consecutive patients with severe aortic stenosis who were referred for TAVI. The procedural, early, and midterm clinical outcomes were compared between patients aged90 years (n = 110, average age 82.3 ± 8.3 years) and ≥90 years (n = 26; average age 91.6 ± 1.9 years). A comparison of the baseline characteristics revealed that among patients aged ≥90 years, the prevalence of women (50% vs 81%, p0.001) and the mean aortic valve gradient (45.5 ± 15.4 vs 56.3 ± 23.4 mm Hg, p = 0.005) were greater than those in patients aged90 years. Major vascular complications occurred more frequently in patients ≥90 years (5% vs 19%, p = 0.022), although the rate of procedural success and 30-day and 6-month mortality were not different between the 2 age groups (96% vs 100%, p = 0.58; 6% vs 15%, p = 0.22; and 14% vs 27%, p = 0.14, respectively). The mortality rates were greater among patients aged ≥90 years. At 6 months, both groups of survivors were similar in symptom status, with a New York Heart Association classification less than class II (89% vs 84%, p = 0.68). The cumulative survival (median 13.4 ± 8.0 months of follow-up) was not significantly different between the 2 age groups (p = 0.22, log-rank test). In conclusion, even very elderly nonagenarians can experience acceptable clinical results and benefits after TAVI.
- Published
- 2012
24. A new modality for assessing aortic calcium score by 3D trans-esophageal echocardiography
- Author
-
N. Benhaiem, Pascal Lim, Leopold Oliver, J.L. Dubois-Randé, D. Fard, Jean-François Deux, J.P. Couetil, Julien Ternacle, Eric Bergoend, Thomas d’Humieres, O. Brault-Meslin, and Costin Radu
- Subjects
Aortic valve ,medicine.medical_specialty ,business.industry ,chemistry.chemical_element ,Region growing algorithm ,Calcium ,medicine.disease ,Cardiac surgery ,Stenosis ,medicine.anatomical_structure ,chemistry ,Peak velocity ,medicine ,In patient ,Cardiology and Cardiovascular Medicine ,Nuclear medicine ,business ,Calcium score - Abstract
Introduction Aortic valve (AV) calcium quantification by cardiac Computed Tomography (cardiac CT) has been proposed as an alternative for AV stenosis quantification when echocardiography is uncertain. To limit X-ray radiation and cost, we developed an alternative AV calcium score based on 3D-transesophageal echocardiography (3D-TOE). Methods The study enrolled 29 patients referred for AV assessment (21 men and 8 women who were 78 ± 11 years old, average transaortic peak velocity was 4.18 ± 1.5 m/s and average mean transaortic gradient was 45 ± 18 mmHg). All patients underwent 3D-TOE and calcium score was derived from AV 3D full volume data using home-made region growing algorithm developed on MatLab® ( Fig. 2 ). Calcium score obtained with 3D-TOE was compared to AV calcium scoring obtained by cardiac CT. In patients referred for cardiac surgery, AV calcium scoring by CT was repeated on the explanted AV and calcium weight was obtained by pathology analysis. Results Calcium score by 3D-TOE (8877 ± 4024 AU) and CT (3155 ± 2360 AU) were fairly correlated (R = 0.88; P Fig. 1 ). Similar correlation was observed with CT calcium score on explanted AV (R = 0.89; P = 0.0014) and pathology data (R = 0.63; P = 0.0516). Inter-observer and intra-observer variability coefficients were 11% and 11%, respectively ( Fig. 1 , Fig. 2 ). Conclusion AV calcium load can be quantified using 3D-TOE. Excellent correlation was observed with AV calcium score obtained by CT.
- Published
- 2018
25. 0314: Biomakers are better than right ventricular function for assessing postoperative mortality in patients referred for tricuspid regurgitation correction
- Author
-
Laureline Faivre, Pascal Lim, Jean-Luc Dubois-Randé, Jean-Luc Monin, Emmanuel Teiger, Jean-Paul Couetil, Clémence Antoine, Julien Ternacle, and Eric Bergoend
- Subjects
medicine.medical_specialty ,Ventricular function ,business.industry ,Regurgitation (circulation) ,Surgical correction ,medicine.disease ,Uremia ,Surgery ,medicine.anatomical_structure ,Fractional area change ,Postoperative mortality ,Internal medicine ,medicine ,Cardiology ,In patient ,Heart valve ,business ,Cardiology and Cardiovascular Medicine - Abstract
BackgroundOperative risk of tricuspid regurgitation (TR) surgery is currently based on right ventricular (RV) systolic function assessment while biological markers of RV congestion are under used. The aim of the study was to assess the additive value of biological markers of RV congestion in predicting postoperative mortality after TR surgery.MethodsThirty-seven patients (age 69±13 years) referred for surgical correction of isolated severe TR (n=13) or TR associated with a left-side heart valve disease were included. RV congestion was assessed preoperatively using natremia, uremia, creatinin and bilirubin. RV systolic function was assessed by echocardiography using tricuspid annular plane systolic excursion (TAPSE) and RV fractional area change (RVFAC). Outcome was defined as early postoperative mortality (
- Published
- 2016
- Full Text
- View/download PDF
26. Localized constrictive pericarditis after Gore-Tex pericardial substitution
- Author
-
Pierre Cosnay, Eric Bergoend, Danielle Casset-Senon, and Michel Marchand
- Subjects
Adult ,Heart Septal Defects, Ventricular ,Male ,Reoperation ,Pulmonary and Respiratory Medicine ,Constrictive pericarditis ,medicine.medical_specialty ,Pericardial constriction ,Aortic Valve Insufficiency ,Radionuclide ventriculography ,Risk Assessment ,Ventricular Function, Left ,Constriction ,Internal medicine ,medicine.artery ,medicine ,Humans ,Pericardium ,Polytetrafluoroethylene ,Radionuclide Ventriculography ,Cardiac imaging ,Bioprosthesis ,Heart Valve Prosthesis Implantation ,Aorta ,business.industry ,Pericarditis, Constrictive ,medicine.disease ,Treatment Outcome ,medicine.anatomical_structure ,Ventricle ,Heart Valve Prosthesis ,Ventricular Function, Right ,cardiovascular system ,Cardiology ,Surgery ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies - Abstract
A 65-year-old patient presented with recurrent cardiac decompensation 12 years after aortic prosthesis replacement and expanded polytetrafluoroethylene (ePTFE) membrane pericardial substitution. Diagnosis of pericardial constriction was difficult. Only one cardiac imaging method, radionuclide ventriculography, was helpful. Upon re-operation, an epicardial fibrous strap which restricted right ventricle (RV) diastolic expansion was found between the anterior free wall and diaphragmatic portion of the RV. Clinical status dramatically improved after surgical removal of this bridle, as did ventricular filling curves in radionuclide imaging. This case shows that delayed cardiac constriction is possible after ePTFE pericardial substitution, especially if the membrane is applied to both anterior and diaphragmatic aspects of the heart.
- Published
- 2010
27. Effect of local anesthetic management with conscious sedation in patients undergoing transcatheter aortic valve implantation
- Author
-
Pascal Lim, Jean-Luc Dubois-Randé, Gauthier Mouillet, Kentaro Meguro, Emmanuel Teiger, Jean-Luc Monin, Masanori Yamamoto, and Eric Bergoend
- Subjects
Male ,medicine.medical_specialty ,Cardiac Catheterization ,medicine.drug_class ,Sedation ,Conscious Sedation ,law.invention ,Postoperative Complications ,law ,Risk Factors ,Cardiac tamponade ,Internal medicine ,Cause of Death ,medicine ,Humans ,Local anesthesia ,Myocardial infarction ,Anesthetics, Local ,Stroke ,Retrospective Studies ,Aged, 80 and over ,Heart Valve Prosthesis Implantation ,Local anesthetic ,business.industry ,Incidence ,Perioperative ,Aortic Valve Stenosis ,medicine.disease ,Intensive care unit ,Survival Rate ,Treatment Outcome ,Anesthesia ,Aortic Valve ,Cardiology ,Female ,France ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Echocardiography, Transesophageal ,Anesthesia, Local ,Follow-Up Studies - Abstract
The present study sought to assess the effectiveness of local anesthesia with conscious sedation (LACS) during transcatheter aortic valve implantation (TAVI). On its introduction, TAVI was mostly performed with the patient under general anesthesia (GA); however, evidence supporting the use of less-invasive LACS has been increasing. The data from 174 consecutive patients who underwent TAVI by way of the femoral artery from December 2007 to December 2011 were analyzed. GA was mainly used in early phase of the study (n = 44); this was gradually shifted to LACS in the late phase (n = 130). The clinical outcomes were compared for those patients who received GA versus LACS. The incidence and causes of “LACS failure,” defined as conversion to GA from LACS during TAVI, were also assessed. The rates of procedural success and 30-day mortality were not different between the 2 groups (93.3% vs 95.3%, p = 0.60; 6.7% vs 7.8%, p = 0.55, respectively). Although the clinical backgrounds of the patients showed differences, these results were not significant after adjusting for other influential confounders. The intensive care unit stay and hospital stay were longer in the GA group than in the LACS group (3.9 ± 2.2 vs 3.3 ± 1.5 days, p = 0.044; and 12.2 ± 8.3 vs 8.1 ± 6.5 days, p = 0.001, respectively). LACS failure occurred in 6 patients (4.6%), and the causes were multifactorial, as follows: cardiac tamponade in 2, cardiac arrest in 2, myocardial infarction in 1, and stroke in 1. In conclusion, transfemoral TAVI with the patient under LACS could be successfully performed in most patients, with the advantage of early recovery, although the perioperative risks involved in the TAVI procedure should be considered.
- Published
- 2012
28. Symptomatic Compression of the Pulmonary Artery by a Thymic Cyst
- Author
-
Eric Bergoend, Marie-Line Hillion, Antonio Fiore, and Jean-Paul Coeutil
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Text mining ,business.industry ,medicine.artery ,Pulmonary artery ,medicine ,Surgery ,Radiology ,Thymic cyst ,Cardiology and Cardiovascular Medicine ,business ,Compression (physics) - Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.